Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care

S Pscherer,1 K Kostev,2 FW Dippel,3 W Rathmann4 1Department of Diabetology, Klinikum Traunstein, Kliniken Südostbayern AG, Traunstein, 2Epidemiology Department, IMS Health, Frankfurt, 3Sanofi-Aventis Deutschland GmbH, Berlin, 4German Diabetes Center, Institute for Biometrics and Epidemiolog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pscherer S, Kostev K, Dippel FW, Rathmann W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	type 2 diabetes fracture risk insulin treatment oral antidiabetic medication primary care Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/cd40dd33a1ab4c33912a897269d61b14
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd40dd33a1ab4c33912a897269d61b14
record_format	dspace
spelling	oai:doaj.org-article:cd40dd33a1ab4c33912a897269d61b142021-12-02T06:56:15ZFracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care1178-7007https://doaj.org/article/cd40dd33a1ab4c33912a897269d61b142016-02-01T00:00:00Zhttps://www.dovepress.com/fracture-risk-in-patients-with-type-2-diabetes-under-different-antidia-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007S Pscherer,1 K Kostev,2 FW Dippel,3 W Rathmann4 1Department of Diabetology, Klinikum Traunstein, Kliniken Südostbayern AG, Traunstein, 2Epidemiology Department, IMS Health, Frankfurt, 3Sanofi-Aventis Deutschland GmbH, Berlin, 4German Diabetes Center, Institute for Biometrics and Epidemiology, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany Aim: Type 2 diabetes is associated with an increased risk of fractures. There are a few studies on the effects of diabetes treatment on fracture risk. The aim was to investigate the fracture risk related to various types of insulin therapy in primary care practices. Methods: Data from 105,960 type 2 diabetes patients from 1,072 general and internal medicine practices in Germany were retrospectively analyzed (Disease Analyzer database; 01/2000–12/2013). Fracture risk of the following therapies was compared using multivariate logistic regression models adjusting for age, sex, diabetes care, comorbidity, and glycemic control (HbAlc): 1) incident insulin therapy versus oral antidiabetic drugs, 2) basal-supported oral therapy versus supplementary insulin therapy versus conventional insulin therapy, and 3) insulin glargine versus insulin detemir versus NPH insulin. Results: There was a lower odds of having incident fractures in the oral antidiabetic drug group compared to incident insulin users, although not significant (odds ratio [OR]; 95% confidence interval: 0.87; 0.72–1.06). There were increased odds for conventional insulin therapy (OR: 1.59; 95% CI [confidence interval] 0.89–2.84) and supplementary insulin therapy (OR: 1.20; 0.63–2.27) compared to basal-supported oral therapy, which was not significant as well. Overall, there was no significant difference in fracture risk for basal insulins (glargine, detemir, NPH insulin). After a treatment duration ≥2 years, insulin glargine showed a lower odds of having ≥1 fracture compared to NPH users (OR: 0.78; 0.65–0.95) (detemir vs NPH insulin: OR: 1.03; 0.79–1.36). Conclusion: Long-standing therapy with insulin glargine was associated with a lower odds of having any fractures compared to NPH insulin. Further studies are required to investigate whether the lower chance is due to a reduced frequency of hypoglycemia. Keywords: type 2 diabetes, fracture risk, insulin treatment, oral antidiabetic medication, primary carePscherer SKostev KDippel FWRathmann WDove Medical Pressarticletype 2 diabetesfracture riskinsulin treatmentoral antidiabetic medicationprimary careSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 17-23 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes fracture risk insulin treatment oral antidiabetic medication primary care Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes fracture risk insulin treatment oral antidiabetic medication primary care Specialties of internal medicine RC581-951 Pscherer S Kostev K Dippel FW Rathmann W Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
description	S Pscherer,1 K Kostev,2 FW Dippel,3 W Rathmann4 1Department of Diabetology, Klinikum Traunstein, Kliniken Südostbayern AG, Traunstein, 2Epidemiology Department, IMS Health, Frankfurt, 3Sanofi-Aventis Deutschland GmbH, Berlin, 4German Diabetes Center, Institute for Biometrics and Epidemiology, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany Aim: Type 2 diabetes is associated with an increased risk of fractures. There are a few studies on the effects of diabetes treatment on fracture risk. The aim was to investigate the fracture risk related to various types of insulin therapy in primary care practices. Methods: Data from 105,960 type 2 diabetes patients from 1,072 general and internal medicine practices in Germany were retrospectively analyzed (Disease Analyzer database; 01/2000–12/2013). Fracture risk of the following therapies was compared using multivariate logistic regression models adjusting for age, sex, diabetes care, comorbidity, and glycemic control (HbAlc): 1) incident insulin therapy versus oral antidiabetic drugs, 2) basal-supported oral therapy versus supplementary insulin therapy versus conventional insulin therapy, and 3) insulin glargine versus insulin detemir versus NPH insulin. Results: There was a lower odds of having incident fractures in the oral antidiabetic drug group compared to incident insulin users, although not significant (odds ratio [OR]; 95% confidence interval: 0.87; 0.72–1.06). There were increased odds for conventional insulin therapy (OR: 1.59; 95% CI [confidence interval] 0.89–2.84) and supplementary insulin therapy (OR: 1.20; 0.63–2.27) compared to basal-supported oral therapy, which was not significant as well. Overall, there was no significant difference in fracture risk for basal insulins (glargine, detemir, NPH insulin). After a treatment duration ≥2 years, insulin glargine showed a lower odds of having ≥1 fracture compared to NPH users (OR: 0.78; 0.65–0.95) (detemir vs NPH insulin: OR: 1.03; 0.79–1.36). Conclusion: Long-standing therapy with insulin glargine was associated with a lower odds of having any fractures compared to NPH insulin. Further studies are required to investigate whether the lower chance is due to a reduced frequency of hypoglycemia. Keywords: type 2 diabetes, fracture risk, insulin treatment, oral antidiabetic medication, primary care
format	article
author	Pscherer S Kostev K Dippel FW Rathmann W
author_facet	Pscherer S Kostev K Dippel FW Rathmann W
author_sort	Pscherer S
title	Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
title_short	Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
title_full	Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
title_fullStr	Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
title_full_unstemmed	Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
title_sort	fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/cd40dd33a1ab4c33912a897269d61b14
work_keys_str_mv	AT pscherers fractureriskinpatientswithtype2diabetesunderdifferentantidiabetictreatmentregimensaretrospectivedatabaseanalysisinprimarycare AT kostevk fractureriskinpatientswithtype2diabetesunderdifferentantidiabetictreatmentregimensaretrospectivedatabaseanalysisinprimarycare AT dippelfw fractureriskinpatientswithtype2diabetesunderdifferentantidiabetictreatmentregimensaretrospectivedatabaseanalysisinprimarycare AT rathmannw fractureriskinpatientswithtype2diabetesunderdifferentantidiabetictreatmentregimensaretrospectivedatabaseanalysisinprimarycare
_version_	1718399720959770624

Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care

Ejemplares similares